Literature DB >> 18406826

Genetic basis of familial neurohypophyseal diabetes insipidus.

L K Hansen1, S Rittig, G L Robertson.   

Abstract

Familial neurohypophyseal diabetes insipidus (FNDI) is an autosomal dominant (adFNDI) or X-linked recessive (xrFNDI) disorder characterized by the development in early childhood of an irreversible deficiency of arginine vasopressin (AVP) secretion. Autopsy data in adFNDI reveal selective destruction of the posterior pituitary magnocellular neurons that normally produce the hormone. These abnormalities are due to a variety of mutations in the gene that encodes the AVP-neurophysin II precursor. Each one predicts a change in the primary structure of the preprohormone, and all but one are of a type known or reasonably presumed to impair the folding and cellular trafficking of the preprohormone. This pattern and the uniform clinical characteristics of adFNDI suggest that the disease is due to the production of a mutant precursor that is toxic for magnocellular neurons, because it cannot be folded, processed, or otherwise disposed of efficiently. Although the gene responsible for xrFNDI has not yet been cloned, the striking clinical similarities between adFNDI and xrFNDI suggest that similar pathophysiologic mechanisms may be involved.

Entities:  

Year:  1997        PMID: 18406826     DOI: 10.1016/s1043-2760(97)00157-4

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  8 in total

Review 1.  Familial forms of diabetes insipidus: clinical and molecular characteristics.

Authors:  Muriel Babey; Peter Kopp; Gary L Robertson
Journal:  Nat Rev Endocrinol       Date:  2011-07-05       Impact factor: 43.330

2.  A novel heterozygous missense mutation in the vasopressin moiety is identified in a Japanese person with neurohypophyseal diabetes insipidus.

Authors:  H Kobayashi; I Fujisawa; K Ikeda; C Son; T Iwakura; A Yoshimoto; M Kasahara; T Ishihara; Y Ogawa
Journal:  J Endocrinol Invest       Date:  2006-03       Impact factor: 4.256

3.  Two novel mutations in seven Czech and Slovak kindreds with familial neurohypophyseal diabetes insipidus-benefit of genetic testing.

Authors:  Gabriela Hrčková; Viktor Jankó; Jitka Kytnarová; Michaela Čižmárová; Markéta Tesařová; Ľudmila Košťálová; Daniela Virgová; Tomáš Dallos; Václav Hána; Jan Lebl; Jiří Zeman; László Kovács
Journal:  Eur J Pediatr       Date:  2016-08-18       Impact factor: 3.183

4.  A murine model of autosomal dominant neurohypophyseal diabetes insipidus reveals progressive loss of vasopressin-producing neurons.

Authors:  Theron A Russell; Masafumi Ito; Mika Ito; Richard N Yu; Fred A Martinson; Jeffrey Weiss; J Larry Jameson
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

5.  Familial neurohypophyseal diabetes insipidus: clinical, genetic and functional studies of novel mutations in the arginine vasopressin gene.

Authors:  Maria Inês Alvelos; Ângela Francisco; Leonor Gomes; Isabel Paiva; Miguel Melo; Pedro Marques; Susana Gama-de-Sousa; Sofia Carreiro; Telma Quintela; Isabel Gonçalves; Manuel Carlos Lemos
Journal:  Pituitary       Date:  2021-01-12       Impact factor: 4.107

Review 6.  Grading Central Diabetes Insipidus Induced by Immune Checkpoint Inhibitors: A Challenging Task.

Authors:  Agnese Barnabei; Lidia Strigari; Andrea Corsello; Rosa Maria Paragliola; Giovanni Maria Iannantuono; Roberto Salvatori; Salvatore Maria Corsello; Francesco Torino
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-21       Impact factor: 5.555

7.  Functional analyses of three different mutations in the AVP-NPII gene causing familial neurohypophyseal diabetes insipidus.

Authors:  Merve Özcan Türkmen; Tugce Karaduman; Beril Erdem Tuncdemir; Mehmet Altay Ünal; Hatice Mergen
Journal:  Endocrine       Date:  2021-07-07       Impact factor: 3.633

8.  Autosomal dominant familial neurohypophyseal diabetes insipidus caused by a novel missense mutation in AVP gene in a large Italian kindred.

Authors:  Maria Grazia Castagna; Marco Capezzone; Carlotta Marzocchi; Silvia Cantara; Alfonso Sagnella
Journal:  Endocrine       Date:  2021-07-28       Impact factor: 3.633

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.